Brind.

The MHRA is reviewing safety concerns and age limits related to the Pathways puberty blocker trial, with arguments that the agency has failed its mission.

1 report, 1 independent Updated Jun 19
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The MHRA is reviewing safety concerns and age limits related to the Pathways puberty blocker trial, with arguments that the agency has failed its mission.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped